Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food effect on surufatinib PK in healthy subjects
NCT04372394Phase 1Completed
- Sponsor
- Hutchison MediPharma (HMP)
- Start
- Aug 2020
- Primary completion
- Oct 2020
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of surufatinib in Neuroendocrine Neoplasm (NEN) (2 arms), sponsored by Hutchison MediPharma (HMP). Primary endpoints: Area Under the Concentration-Time Curve From Time Zero to Last Quantifiable Concentration, Area Under the Concentration-Time Curve and 1 more. Started Aug 2020; status: completed.
02
Drugs
surufatinib
03
Conditions
Neuroendocrine Neoplasm (NEN)
Beyond the preview
Go deeper on NCT04372394.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04372394.